Furthermore, in gastric cancer patients with a variety of clinicopathological features, such as T stage 2 or 4 or N+ stage, M0 stage, surgery, 5-FU-based adjuvant therapy, other adjuvant therapy, and negative HER2, increased RECK expression was linked to a worse prognosis (Table 3, p < 0.05). The gene discussed is ERBB2; the disease is gastric cancer.